A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Kymera Therapeutics, Inc.
Study ID
NCT07217015
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • KT-621 — DRUG
    Oral drug
  • Placebo — OTHER
    Oral placebo matched to KT-621

Study Details

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

Key Dates

Start date
Nov 24, 2025
Status verified
Jan 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group 1: KT-621 Dose 1
  • Experimental: Group 2: KT-621 Dose 2
  • Experimental: Group 3: KT-621 Dose 3
  • Placebo Comparator: Group 4: Placebo

Primary Outcome Measure

Change from baseline in Eczema Area and Severity Index (EASI) score [ Time Frame: From baseline through Week 16 ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
Kymera Investigative SiteBirminghamAlabama35244-
Kymera Investigative SiteNorth Little RockArkansas72117-
Kymera Investigative SiteFreemontCalifornia94538-
Kymera Investigative SiteLos AngelesCalifornia90025-
Kymera Investigative SiteLos AngelesCalifornia90045-
Kymera Investigative SiteSanta MonicaCalifornia91350-
Kymera Investigative SiteDelray BeachFlorida33484-
Kymera Investigative SiteMiamiFlorida33137-
Kymera Investigative SiteMiramarFlorida33027-
Kymera Investigative SiteNormalIllinois61761-
Kymera Investigative SiteIndianapolisIndiana46202-
Kymera Investigative SiteAnn ArborMichigan48103-
Kymera Investigative SiteDetroitMichigan48202-
Kymera Investigative SiteThe BronxNew York10455-
Kymera Investigative SiteFargoNorth Dakota58103-
Kymera Investigative SitePortlandOregon97201-
Kymera Investigative SitePortlandOregon97239-
Kymera Investigative SitePhiladelphiaPennsylvania19103-
Kymera Investigative SiteSan AntonioTexas78213-
Kymera Investigative SiteSan AntonioTexas78218-

Find similar trials in Birmingham, AL

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Kymera Investigative Site· Birmingham, ALKymera Investigative Site· North Little Rock, ARKymera Investigative Site· Freemont, CAKymera Investigative Site· Los Angeles, CAKymera Investigative Site· Santa Monica, CAKymera Investigative Site· Delray Beach, FL

Related Studies